A single-center prospective observational study to evaluate the safety and efficacy of sentinel lymph node navigation surgery (SNNS) for uterine malignancies

未提供0 个研究点目标入组 196 人开始时间: 待定

适应症

试验速览

暂无简介。

•Clinically diagnosed with uterine cervical cancer or endometrial cancer.
•Histologically confirmed diagnosis of the following:
•For cervical cancer: Squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
•For endometrial cancer: Endometrioid carcinoma, serous carcinoma, or clear cell carcinoma.
•Clinical stage (per JSGO 2020 / FIGO 2018 for cervical cancer; JSGO 2011 / FIGO 2008 for endometrial cancer) meets the following:
•Cervical cancer: Stage IA1 (with lymphovascular space invasion), IA2, IB1, IB2, or IIA
•Endometrial cancer: Stage IA or IB.
•Aged 18 to 79 years at the time of informed consent.
•ECOG Performance Status (PS) of 0 or
•No prior treatment for uterine cervical cancer or endometrial cancer.
•Provision of written informed consent. (For cases where SNNS was performed as routine clinical care before protocol approval, registration is permitted if written consent is obtained after approval.)
•Patients undergoing fertility-sparing surgery for cervical cancer (e.g., conization, trachelectomy) are also eligible.

•Presence of active double cancer (synchronous multiple cancers/multicentric cancers or metachronous multiple cancers/multicentric cancers with a disease-free interval of less than 5 years; however, carcinoma in situ is excluded).
•History of prior radiation therapy to the abdomen or pelvis.
•Pregnant or possibly pregnant.
•Deemed by the attending physician to have difficulty participating in the study for other clinical reasons.
•Otherwise judged as ineligible by the principal investigator for any other reason.

发起方

未提供